We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Profacgen's ADCP Assay Services provide quantitative, reproducible evaluation of antibody-dependent cellular phagocytosis, enabling precise characterization of Fcγ receptor-mediated macrophage engulfment across therapeutic antibody development workflows.
Antibody-dependent cellular phagocytosis (ADCP) is a critical Fc effector mechanism in which the Fc region of an antibody bound to a target cell engages Fcγ receptors on macrophages, triggering receptor clustering, intracellular signaling, cytoskeletal rearrangement, and directed engulfment of the antibody-opsonized target. The ability to measure ADCP with physiological relevance, platform flexibility, and analytical rigor directly supports oncology antibody development, macrophage-engaging therapeutic design, Fc optimization, biosimilar comparability, and candidate prioritization decisions.
Overview of ADCP Mechanism
Figure 1. ADCP mechanism: antibody opsonization of target cell, Fcγ receptor recognition by macrophages, cellular activation, phagocytosis, and target clearance. (Hendriks et al., 2017)
ADCP proceeds through a sequential, Fcγ receptor-mediated cascade that links antigen recognition on target cells to innate immune phagocytic clearance:
Target Cell: Antigen-expressing target cells are identified and bound by the Fab region of the therapeutic antibody, establishing an opsonized surface for immune recognition
Antibody Opsonization: Bivalent antibody engagement coats the target cell surface, positioning the Fc region for Fcγ receptor interaction and creating an opsonic signal for phagocytic cells
Fcγ Receptor Recognition: Macrophage Fcγ receptors (FcγRI, FcγRIIa, FcγRIIIa) bind to the antibody Fc region, with receptor clustering and ITAM/ITIM signaling initiating intracellular activation cascades
Macrophage Activation: Receptor engagement triggers Syk kinase activation, PI3K signaling, and cytoskeletal reorganization, preparing the phagocyte for engulfment and preparing phagolysosomal machinery
Phagocytosis: Activated macrophages extend pseudopodia around the opsonized target, enclosing it within a phagocytic cup that matures into an intracellular phagosome
Target Clearance: Phagosome-lysosome fusion delivers hydrolytic enzymes and reactive oxygen species, degrading the engulfed target and presenting antigens for adaptive immune coordination
Quantitative assessment of each phagocytic step—and of the integrated clearance cascade—enables mechanistic understanding, potency determination, Fc engineering guidance, and comparability evaluation across antibody candidates and manufacturing lots.
Our ADCP Assay Platforms
Profacgen provides multiple ADCP assay platforms to accommodate diverse antibody formats, target cell types, effector cell sources, and program requirements. Platform selection is guided by desired physiological relevance, donor flexibility, reproducibility, and analytical resolution.
Primary Macrophage ADCP Assays
High physiological relevance evaluation using primary human macrophages derived from peripheral blood or tissue sources.
Fresh and cryopreserved monocyte-derived macrophage (MDM) preparation and phenotypic qualification
M1/M2 polarization state characterization for disease-relevant phagocytic context
Direct phagocytosis quantification by flow cytometry, imaging, or metabolic readout
Ideal for mechanism-of-action studies, Fc engineering evaluation, and clinical relevance assessment
Monocyte-Derived Macrophage Assays
Flexible donor sourcing with standardized differentiation protocols for consistent effector populations.
Peripheral blood mononuclear cell isolation and monocyte enrichment
GM-CSF or M-CSF-driven differentiation with defined maturation timelines
Suitable for donor diversity studies, population pharmacogenomics, and biosimilar comparability
THP-1-Based ADCP Assays
Highly reproducible evaluation using the THP-1 monocytic cell line differentiated into macrophage-like effector cells.
PMA or vitamin D3-driven differentiation into adherent, phagocytically competent macrophages
Defined Fcγ receptor expression profiles and consistent effector-to-target ratios
Minimized donor variability and assay drift across batches and timepoints
Optimized for screening campaigns, lot release, and high-throughput comparability studies
Imaging-Based ADCP Assays
Direct visualization and quantitative morphological analysis of phagocytic events.
Live-cell or fixed-cell confocal and widefield microscopy with fluorescent target labeling
Time-lapse imaging of phagocytic cup formation, engulfment, and phagosome maturation
Automated image analysis for phagocytosis score, engulfment kinetics, and target degradation
Recommended for detailed mechanistic characterization, morphology studies, and publication-grade data
Flow Cytometry-Based ADCP Assays
Quantitative multiparametric analysis of phagocytosis efficiency and effector cell activation.
Dual-fluorescent labeling distinguishing external target binding from internalized engulfment
Simultaneous assessment of phagocytosis, effector activation markers (CD11b, CD14), and viability
High-throughput compatible with 96-well formats and automated acquisition
Ideal for dose-response profiling, EC50 determination, and screening applications
Assay Readouts
Profacgen supports multiple quantitative readouts to capture distinct aspects of ADCP biology, enabling comprehensive characterization aligned with program objectives:
Figure 2. Protocol for assessing antibody-dependent cellular phagocytosis. (Sevilla et al., 2025)
Phagocytosis Score: Integrated metric combining percent phagocytosis and phagocytic index into a single potency parameter for comparative assessment and ranking
Percent Phagocytosis: Proportion of effector cells that have internalized at least one target cell, measured by flow cytometry or imaging-based enumeration
Phagocytic Index: Average number of target cells internalized per effector cell, providing a measure of engulfment capacity and efficiency
Fcγ Receptor Activation: Assessment of receptor clustering, ITAM phosphorylation, and downstream signaling markers (Syk, PI3K, Akt) using flow cytometry or western blot
Cytokine Production: Multiplex quantification of macrophage-derived cytokines (TNF-α, IL-6, IL-1β, IL-10) using ELISA to assess immune modulation concurrent with phagocytosis
Advanced ADCP Characterization
Profacgen's ADCP assays support advanced characterization to elucidate structure-function relationships, guide Fc engineering, and enable mechanistic understanding:
Fc Variant Comparison: Side-by-side ADCP assessment of amino acid substitutions (e.g., GASDALIE, LALA, YTE) designed to enhance or reduce FcγRIIa/FcγRIIIa binding and phagocytic potency
Glycosylation Impact Analysis: Evaluation of afucosylated, bisecting, high-mannose, or sialylated glycoforms for altered Fcγ receptor affinity and ADCP activity, correlating glycan structure with phagocytic outcomes
Mechanism Studies: Detailed characterization of receptor dependency (FcγRI, FcγRIIa, FcγRIIIa blocking), signaling pathway involvement, and phagolysosomal processing to support target biology understanding and regulatory documentation
Applications
Our ADCP assays support a broad spectrum of applications across therapeutic antibody development and characterization:
Oncology Antibody Development: Quantitative assessment of macrophage-mediated tumor cell clearance to support lead selection, mechanism-of-action validation, and combination strategy design for oncology indications
Macrophage-Engaging Antibodies: Evaluation of bispecific and engineered antibodies specifically designed to recruit and activate macrophages for enhanced phagocytic clearance of cancer cells or pathogens
Fc Optimization: Iterative refinement of antibody candidates based on structure-ADCP relationships, Fcγ receptor binding profiles, and glycoengineering data to enhance or attenuate phagocytic activity
Biosimilar Evaluation: Rigorous side-by-side comparability testing to demonstrate functional equivalence in ADCP potency between innovator and biosimilar products
Candidate Prioritization: High-throughput screening and ranking of antibody panels based on phagocytic potency metrics, enabling data-driven selection of development candidates
Deliverables
Profacgen provides structured, decision-ready documentation aligned with your program's analytical and regulatory requirements:
Phagocytosis metrics: Comprehensive quantification including percent phagocytosis, phagocytic index, and integrated phagocytosis score with replicate data and statistical precision
Dose-response analysis: Complete concentration-response relationships with EC50, Emax, and Hill slope parameters calculated using nonlinear regression (4-parameter logistic or sigmoidal models)
Statistical evaluation: Appropriate modeling with 95% confidence intervals, goodness-of-fit metrics, replicate precision, and equivalence testing for comparability studies
Comprehensive study report: Detailed documentation of assay methods, effector cell qualification, raw data, analyzed results, and interpretative summaries suitable for regulatory review, internal decision-making, or publication support
A therapeutic antibody development program required quantitative ADCP data to guide optimization of a macrophage-engaging bispecific antibody designed to enhance tumor cell phagocytosis. The candidate incorporated an Fc region engineered for selective FcγRIIa binding and a tumor-associated antigen binding arm, requiring functional validation of the phagocytic mechanism.
Objective:
To generate reproducible, statistically robust ADCP potency data across multiple bispecific candidates and Fc variants using primary macrophage and THP-1-based assays, enabling identification of a lead with optimized phagocytic activity and favorable Fcγ receptor selectivity.
Approach:
Profacgen implemented a tiered ADCP evaluation strategy: primary monocyte-derived macrophage assays for physiological relevance and THP-1 differentiated macrophage assays for high-throughput screening. Dose-response curves were generated for each candidate with multiple target cell lines. Parallel Fcγ receptor binding assays (FcγRI, FcγRIIa, FcγRIIIa) were conducted to correlate biophysical receptor affinity with functional phagocytic outcomes. Imaging-based assays confirmed phagocytic cup formation and target internalization kinetics.
Outcome:
The program identified a lead bispecific candidate with significantly enhanced ADCP potency relative to parental antibody formats, supported by selective FcγRIIa engagement and robust phagocytic index improvement. The structured dataset enabled confident progression to in vivo efficacy evaluation and regulatory discussion of the macrophage-engaging mechanism.
A biosimilar development program required rigorous demonstration of functional equivalence in ADCP activity between a candidate antibody and the reference innovator product. ADCP potency was a critical quality attribute for regulatory approval, necessitating a powered comparability study with qualified methods and multiple effector cell sources.
Objective:
To execute a statistically powered ADCP comparability study demonstrating that the biosimilar candidate falls within the predefined equivalence margin for phagocytosis score, percent phagocytosis, and phagocytic index relative to the reference product, using both primary and THP-1 effector cell platforms.
Approach:
Profacgen conducted side-by-side ADCP assays using qualified primary monocyte-derived macrophages from multiple donors and differentiated THP-1 cells. Assay qualification included precision, linearity, specificity, and robustness evaluation across effector cell sources. Multiple independent runs were performed with appropriate statistical analysis to assess equivalence using two one-sided tests (TOST) and confidence interval approaches. Fcγ receptor allotype stratification and cytokine production analysis were included to demonstrate comprehensive functional equivalence.
Outcome:
The biosimilar candidate demonstrated ADCP potency, phagocytic metrics, and Fcγ receptor activation profiles within the predefined equivalence margin across all assay conditions, effector cell sources, and statistical analyses. The comprehensive dataset and structured report supported regulatory submission and accelerated the path to clinical development.
Q: What is ADCP and how does it differ from ADCC and CDC?
A: ADCP (Antibody-Dependent Cellular Phagocytosis) is an Fc-mediated immune mechanism in which macrophages engulf antibody-opsonized target cells through Fcγ receptor engagement. ADCC involves NK cell-mediated killing through FcγRIIIa, while CDC involves complement-mediated lysis through C1q and the membrane attack complex. ADCP is mediated primarily by macrophages and requires target internalization, whereas ADCC and CDC result in direct target cell destruction.
Q: Which Fcγ receptors are most important for ADCP?
A: ADCP is primarily mediated by FcγRIIa (CD32a) on macrophages, with contributions from FcγRI (CD64) and FcγRIIIa (CD16a). FcγRIIa is considered the dominant activating receptor for phagocytosis, and its H131R polymorphism significantly affects binding affinity and phagocytic potency. Fc engineering strategies often target FcγRIIa to enhance or reduce ADCP activity independently of ADCC.
Q: Which effector cell source is most appropriate for ADCP assays?
A: Primary monocyte-derived macrophages offer the highest physiological relevance and are preferred for mechanism-of-action and clinical relevance studies. THP-1 cells provide high reproducibility and are ideal for screening, lot release, and comparability studies. Platform selection depends on program stage, desired throughput, and regulatory context. Profacgen can advise on the optimal approach for your specific requirements.
Q: How does Fc engineering affect ADCP potency?
A: Fc engineering can modulate ADCP through modifications that enhance or reduce FcγRIIa binding. Amino acid substitutions such as GASDALIE increase FcγRIIa and FcγRIIIa affinity, enhancing both ADCP and ADCC. LALA (L234A/L235A) and N297A mutations reduce FcγR binding and attenuate effector functions. Glycoengineering, particularly afucosylation, increases FcγRIIIa binding (enhancing ADCC) but can also affect FcγRIIa interactions. Specific engineering strategies can selectively modulate ADCP.
Q: Can ADCP assays support regulatory submissions and lot release?
A: Yes. Profacgen can execute ADCP assays under method qualification or validation protocols aligned with ICH Q2(R1) and regulatory expectations for cell-based potency assays. Structured documentation, statistical analysis, and assay performance characterization support IND-enabling studies, BLA submissions, biosimilar comparability packages, and routine lot release testing.
Q: How is donor variability controlled in primary macrophage ADCP assays?
A: For primary macrophage assays, we implement donor qualification criteria including Fcγ receptor allotype characterization (FcγRIIa H131R, FcγRIIIa V158F), differentiation protocol standardization, and internal reference standards. Multiple independent donors are used to assess population variability. THP-1-based assays eliminate donor variability entirely. All platforms include appropriate positive controls, negative controls, and reference antibodies to monitor assay performance.
References:
Antibody-based cancer therapy. In: International Review of Cell and Molecular Biology. Vol 331. Elsevier; 2017:289-383. doi:10.1016/bs.ircmb.2016.10.002
Sevilla CM, Mijacika A, Somoza B, Osorio JC. Protocol for assessing antibody-dependent cellular phagocytosis by primary murine and human macrophages. STAR Protocols. 2025;6(2):103787. doi:10.1016/j.xpro.2025.103787
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. ADCP mechanism: antibody opsonization of target cell, Fcγ receptor recognition by macrophages, cellular activation, phagocytosis, and target clearance. (Hendriks et al., 2017)
Figure 2. Protocol for assessing antibody-dependent cellular phagocytosis. (Sevilla et al., 2025)